In this way, unlike EGFR exon 19 deletions and point mutations in exon 21, most NSCLC tumors harboring EGFR exon 20 insertion mutations do not benefit from EGFR-TKIs with response rates reported to be below 5% and short intervals of disease control [28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.